Congratulations to Calliditas Therapeutics on their dual listing on NASDAQ US



Today marks a milestone for Industrifonden as our portfolio company Calliditas Therapeutics was listed on NASDAQ in the US, only two years after their initial listing on Nasdaq Stockholm. As the company’s largest shareholder, we are happy to continue to support Calliditas on their journey and we welcome all new international investors to the company. Industrifonden was the first institutional investor in Calliditas Therapeutics and has remained the largest shareholder over the years.

The dual listing on NASDAQ US represents a major milestone for Calliditas in its ambitions to get the oral drug Nefecon registered for US market approval in severe kidney inflammation. At Industrifonden we are very proud to see this dual listing happen. It is a further stepping stone towards providing new therapy to severely sick patients globally in an orphan disease with high unmet medical need.

More information is to be found in today’s press release by Calliditas Therapeutics.

/ Patrik Sobocki, Investment Manager